Observational studyFuture oncology (London, England)2025
Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma.
Observational study in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Post-marketing surveillance of tirabrutinib for Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma in Japan.Journal of clinical and experimental hematopathology : JCEH · 2026Article
- Durable Complete Remission Achieved by Tirabrutinib Rechallenge in Relapsed Primary Central Nervous System Lymphoma: A Case Report.NMC case report journal · 2026Article
- Dynamic changes in serum IL-6, TNF-Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis post-marketing surveillance evaluated the safety and effectiveness of tirabrutinib in patients with relapsed/refractory primary central nervous system lymphoma (r/r PCNSL) in a real-world setting in Japan.
methodsAll patients with r/r PCNSL who started treatment with tirabrutinib between May 20 and 31 October 2020, were registered. Adverse drug reactions (ADRs) and effectiveness were assessed over 52-weeks from the start of tirabrutinib treatment.
resultsOf the 189 patients assessed for safety, 52.4% were male, the median age was 70.0 years (range 30-88), and 49.2% of patients had a Karnofsky performance status score of ≤60. ADRs of any grade and grade ≥3 were observed in 55.6% and 24.3% of patients, respectively. The most common ADRs were rash (11.6%), neutrophil (10.1%) and platelet (5.3%) count decreased. Most of the ADRs corresponding to infections, clinically significant skin disorders, myelosuppression, hypersensitivity, interstitial lung diseases, hepatic function disorders, and hemorrhages resolved or were in the process of resolving. Among the 121 patients assessed for effectiveness, the overall response rate evaluated by the treating physicians was 61.2%, and the 365-day survival rate was 69.8%.
conclusionThis surveillance confirmed the tolerability and effectiveness of tirabrutinib in patients with r/r PCNSL in the real-world setting. CLINICAL
trial registrationJapan Registry of Clinical Trials: jRCT2011210002.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.